logo

MURA(Delisted)

Mural Oncology·NASDAQ
--
--(--)
7.29 / 10
Outperform

Fundamentals show strength in cash flow (PCF: 3/3) and margin ratios (GPM: 2/3) despite weak sales (PS: 1/3). Key bullish factors include EV/EBIT (-0.42, 13.9% returns) and PB (0.54, 12.3% returns), though CFOA (-1.32) and income tax ratios (-5.88%) remain drag factors.

Fundamental(7.29)SentimentTechnical

Analysis Checks(7/10)

PB
Value0.54
Score3/3
Weight12.00%
1M Return12.26%
PCF
Value-0.41
Score3/3
Weight16.13%
1M Return14.21%
PS
Value626.66
Score1/3
Weight7.87%
1M Return7.61%
EV/EBIT
Value-0.42
Score3/3
Weight14.97%
1M Return13.92%
PE
Value-9.62
Score3/3
Weight13.72%
1M Return13.24%
GPM
Value-0.18
Score2/3
Weight9.58%
1M Return9.49%
GMAR
Value-0.15
Score3/3
Weight10.65%
1M Return10.44%
PB-ROE
Value-0.51
Score3/3
Weight12.51%
1M Return12.69%
Income tax / Total profit (%)
Value-5.88
Score0/3
Weight-1.03%
1M Return-1.42%
CFOA
Value-1.32
Score0/3
Weight3.59%
1M Return4.36%
Is MURA undervalued or overvalued?
  • MURA scores 7.29/10 on fundamentals and holds a Discounted valuation at present. Backed by its -86.69% ROE, 0.00% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 24.18% earnings growth, these metrics solidify its Outperform investment rating.